By Layla Zulfa 
A US judge on Thursday delivered a significant blow to personal care giant Kenvue, rejecting the company’s motion to dismiss a lawsuit brought by Texas Attorney General Ken Paxton. The lawsuit accuses Kenvue of failing to adequately warn consumers about potential risks associated with pregnant women taking Tylenol (acetaminophen), specifically regarding alleged links to neurodevelopmental disorders in children. This ruling clears the path for the contentious litigation to proceed, intensifying scrutiny on one of the world’s most widely used over-the-counter medications and the responsibilities of pharmaceutical manufacturers regarding product labeling.
The decision, issued by U.S. District Judge Jeffrey Brown, presiding over the multi-district litigation (MDL) consolidating thousands of similar lawsuits against Kenvue and its former parent company, Johnson & Johnson, underscores the growing legal challenges facing the manufacturers of acetaminophen products. While the judge’s order specifically addresses the Texas Attorney General’s case, it resonates deeply within the broader legal landscape where plaintiffs allege that prenatal exposure to acetaminophen can lead to conditions such as Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD). Kenvue, which maintains that Tylenol is safe when used as directed and that claims linking it to autism are scientifically unproven, now faces the prospect of extensive discovery and potentially a trial.
The Legal Challenge Unfolds: Texas Attorney General vs. Kenvue
Texas Attorney General Ken Paxton initiated his lawsuit against Kenvue, formerly the consumer health division of Johnson & Johnson, alleging that the company engaged in deceptive trade practices by not providing sufficient warnings about the potential risks of Tylenol use during pregnancy. The core of the complaint centers on the legal principle of "duty to warn," arguing that Kenvue possessed, or should have possessed, knowledge of scientific studies suggesting a correlation between prenatal acetaminophen exposure and neurodevelopmental issues, yet failed to update its product labeling accordingly. This alleged omission, according to the state of Texas, misleads consumers and places pregnant women and their unborn children at undue risk.
Kenvue’s motion to dismiss argued primarily on the grounds of preemption and a lack of scientific causation. The company contended that federal law, specifically the Food, Drug, and Cosmetic Act (FDCA), preempts state-level failure-to-warn claims because the U.S. Food and Drug Administration (FDA) has ultimate authority over drug labeling. Kenvue also asserted that the scientific evidence presented by the plaintiffs was insufficient to establish a causal link between acetaminophen use during pregnancy and neurodevelopmental disorders, thus rendering the warning unnecessary and unsupported. Judge Brown’s rejection of the dismissal bid indicates that, at this stage, he found the plaintiffs’ arguments strong enough to warrant further legal proceedings, signifying that the preemption defense and the challenge to scientific causation did not hold sufficient weight to stop the case before discovery.
Acetaminophen and Pregnancy: A Deep Dive into the Scientific Debate
Acetaminophen, the active ingredient in Tylenol, is one of the most commonly used medications globally, particularly among pregnant women, due to its perceived safety profile for pain relief and fever reduction. Estimates suggest that between 50% and 70% of pregnant women use acetaminophen at some point during their pregnancy. For decades, medical professionals have generally considered it the safest option for managing pain and fever during gestation, especially compared to non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, which carry clearer risks in certain trimesters.
However, over the past two decades, a growing body of epidemiological research, primarily observational studies, has begun to raise questions about acetaminophen’s long-term effects on fetal development, particularly concerning neurodevelopmental outcomes. Numerous studies, including those published in prestigious journals, have reported associations between prenatal exposure to acetaminophen and an increased risk of ADHD, ASD, and other behavioral problems in children. For instance, a meta-analysis published in JAMA Pediatrics in 2017 reviewed multiple cohort studies and found a consistent, albeit modest, association between acetaminophen use during pregnancy and an elevated risk of ADHD symptoms and ADHD diagnosis in offspring. Subsequent studies have continued to explore these links, with some research suggesting dose-response relationships or critical windows of exposure during pregnancy.
Despite these observed associations, the scientific community largely agrees that a definitive causal link has not been established. Observational studies, by their nature, can only identify correlations, not causation. Confounding factors, such as the underlying conditions for which acetaminophen is taken (e.g., chronic pain, fever from infection), genetic predispositions, and other environmental influences, are incredibly difficult to fully account for. Critics of the lawsuits emphasize that these studies are not randomized controlled trials, which are considered the gold standard for establishing causality in medicine. Organizations like the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) have acknowledged the emerging research but continue to advise that acetaminophen remains the preferred analgesic for pain and fever during pregnancy, recommending that pregnant individuals use the lowest effective dose for the shortest duration necessary and consult their healthcare providers. They advocate for more robust research to clarify any potential risks.
The central tension in these lawsuits lies precisely in this scientific uncertainty: at what point does a pattern of observed associations become compelling enough to trigger a manufacturer’s "duty to warn," even in the absence of absolute scientific proof of causation? Plaintiffs argue that the cumulative evidence, even if not definitive, is sufficient to warrant a warning, especially given the vulnerability of pregnant women and the potential severity of neurodevelopmental disorders.
Kenvue’s Stance and Corporate Background
Kenvue was officially spun off from Johnson & Johnson (J&J) in August 2023, becoming an independent, publicly traded company. This separation was a strategic move by J&J to streamline its focus on pharmaceuticals and medical devices, while Kenvue inherited a vast portfolio of iconic consumer health brands, including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, and Aveeno. This spin-off means Kenvue is now the primary defendant in the Tylenol litigation, although J&J’s historical role as the original manufacturer means it may still face some liability or be implicated in certain aspects of the legal proceedings.
Throughout the unfolding legal challenges, Kenvue has consistently and vehemently defended the safety of Tylenol. The company has issued statements reiterating its commitment to scientific rigor and public health, asserting that Tylenol, when used according to label instructions, is a safe and effective medication. Kenvue highlights that decades of widespread use and extensive regulatory review by bodies like the FDA have affirmed acetaminophen’s safety profile. The company’s legal defense relies heavily on the argument that the claims linking Tylenol to autism and ADHD are not supported by conclusive scientific evidence and that any attempt to force new warnings based on inconclusive data would be misleading to consumers and undermine the FDA’s authority. From a corporate perspective, the outcome of these lawsuits could have profound financial and reputational implications for Kenvue, potentially affecting its market valuation, consumer trust, and its ability to market one of its flagship products.
The Broader Legal Landscape: Multi-District Litigation (MDL)
The lawsuit brought by the Texas Attorney General is not an isolated incident but rather a component of a much larger legal battle. In October 2022, the U.S. Judicial Panel on Multi-District Litigation (JPML) consolidated dozens of similar lawsuits into a single MDL, titled "In re: Acetaminophen — ASD/ADHD Products Liability Litigation" (MDL No. 3043), in the U.S. District Court for the Southern District of New York. Judge Denise Cote oversees this MDL, which now encompasses thousands of individual and class-action lawsuits filed by parents across the country who allege that their children developed ASD or ADHD due to prenatal exposure to acetaminophen.
The creation of an MDL streamlines complex litigation involving numerous similar cases against common defendants. It centralizes pretrial proceedings, discovery, and motions, aiming for efficiency and consistency in rulings. Judge Brown’s ruling in the Texas Attorney General’s case, while specific to that particular plaintiff, offers a glimpse into the legal arguments and judicial interpretations that will likely shape the outcomes of other cases within the broader MDL. The plaintiffs in the MDL are seeking substantial damages, arguing that manufacturers should have provided stronger warnings about potential neurodevelopmental risks. The sheer volume of these cases represents a significant potential financial liability for Kenvue.
Regulatory Framework and Labeling Standards
The U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating over-the-counter drug labeling. For a drug manufacturer to change its label to include new warnings, it typically needs to either submit new scientific data to the FDA for review and approval or follow FDA guidance. The FDA’s current stance is that acetaminophen is safe for use during pregnancy, and its approved labeling does not include specific warnings about autism or ADHD.
Kenvue and other manufacturers argue that unilaterally adding warnings not mandated by the FDA would violate federal labeling regulations and could be considered misbranding. This is the crux of their preemption defense: if the FDA has approved a label, state-level requirements for different warnings are preempted. However, plaintiffs often counter this by arguing that manufacturers have a common-law duty to warn consumers about known or knowable risks, even if the FDA has not yet mandated a label change, especially if new scientific evidence emerges after initial approval. This legal nuance is often central to product liability cases involving pharmaceuticals. As of now, the FDA has not issued any updated guidance or mandated new warnings for acetaminophen specifically related to neurodevelopmental risks in pregnancy, indicating that the agency’s current assessment does not deem the scientific evidence conclusive enough to warrant such a change.
Implications for Kenvue and the Pharmaceutical Industry
The Texas judge’s rejection of Kenvue’s dismissal bid carries significant implications. For Kenvue, it means continued legal battles, potentially leading to lengthy and costly discovery processes, expert testimony, and possibly bellwether trials within the MDL. A negative outcome, such as a large jury verdict, could have a substantial impact on the company’s financial health and stock performance. Beyond financial costs, the litigation could severely damage Kenvue’s brand reputation, particularly for Tylenol, which has long been a trusted household name. Consumer confidence, especially among pregnant women and new parents, could erode, potentially affecting sales and market share.
More broadly, this case, along with the larger MDL, sets a precedent for how the courts interpret "duty to warn" in the context of evolving scientific understanding and the FDA’s regulatory authority. It could influence future drug labeling practices across the pharmaceutical industry, particularly for over-the-counter medications that are widely used. Manufacturers might face increased pressure to proactively monitor emerging scientific research and consider updating warnings even when definitive causation is not yet fully established, potentially leading to more cautious labeling practices. This could also embolden other state attorneys general to pursue similar consumer protection lawsuits against drug manufacturers.
Looking Ahead: The Path to Trial and Public Health Considerations
With the dismissal motion denied, the Texas Attorney General’s lawsuit against Kenvue will now move into the discovery phase. This will involve extensive exchange of documents, depositions of company executives, scientists, and medical experts. Both sides will seek to bolster their arguments regarding scientific causation, Kenvue’s knowledge of potential risks, and the adequacy of its warnings. It is possible that the parties may engage in settlement discussions at various stages, especially given the potential costs and uncertainties of a trial. However, if no settlement is reached, the case could ultimately proceed to trial.
In parallel, the broader MDL will continue its progression, with Judge Cote likely overseeing similar pretrial motions and potentially selecting "bellwether" cases for early trials. These initial trials are often used to gauge how juries react to the evidence and arguments, helping to inform future settlement negotiations or strategies for remaining cases.
From a public health standpoint, the ongoing litigation highlights the complexities of medication use during pregnancy. While the scientific debate continues, healthcare providers consistently advise pregnant individuals to exercise caution with all medications, including over-the-counter drugs. The recommendation remains to consult with a doctor or pharmacist before taking any medication during pregnancy, to use the lowest effective dose, and for the shortest duration possible. This approach, rooted in the precautionary principle, emphasizes minimizing potential risks where scientific certainty is still evolving, even as the legal system grapples with assigning responsibility for informing consumers about those very uncertainties. The outcome of these Tylenol lawsuits will undoubtedly shape both corporate liability and consumer awareness for years to come.